← Leaderboards
Mark Kester
Pennsylvania State Univ Hershey Med Ctr
$13,621,664
Attributed
$20,517,490
Total exposure
19
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.9M · FY2005–21$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$34,601,891 · 20
By mechanism
P01$25,294,506 · 11
R01$8,500,534 · 6
R03$442,127 · 1
R21$354,724 · 1
R13$10,000 · 1
Top collaborators
- Thomas P Loughran17 shared
- Hong-Gang Wang10 shared
- Shantu G Amin5 shared
- Myles C Cabot5 shared
- David F Claxton5 shared
- Todd E Fox5 shared
- Jiangang Liao5 shared
- Guangfu Li5 shared
Most similar at Pennsylvania State Univ Hershey Med Ctr
Same institution · by research overlap
- Kevin Finnbar Staveleyo'carroll$5,239,458
- Eric T. Kimchi$462
- Christopher Norbury$13,146,672
Others in their field
Top investigators on “Sphingolipids”
- Yusuf Awni Hannun · Medical University Of South Carolina$30,274,744
- Timothy Tun Hla · Boston Children'S Hospital$22,231,469
- Sarah Spiegel · Virginia Commonwealth University$19,116,930
- Besim Ogretmen · Medical University Of South Carolina$18,386,608
- Julie D Saba · University Of California, San Francisco$15,245,252
- Charles E Chalfant · Va Veterans Administration Hospital$12,100,824
Research focus
SphingolipidsBaseMetabolismCeramidesIn VivoMalignant NeoplasmsLipidsTherapeutic TargetMolecularApoptosisCellsInhibitor/AntagonistApoptoticResourcesProgramsSamplingIn VitroMediatingEnzymesAnimal ModelDesignMouse ModelInnovationNanoliposome
Grant awards (83)
Targeted Sphingolipid Metabolism for Treatment of AML$1,995,479
P01 · FY2021 · CA
Clinical Trial of Ceramide nanoLiposomes in AML$571,918
P01 · FY2021 · CA · contact PI
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$553,074
R01 · FY2021 · CA
Targeted Sphingolipid Metabolism for Treatment of AML$2,054,089
P01 · FY2020 · CA
Clinical Trial of Ceramide nanoLiposomes in AML$603,354
P01 · FY2020 · CA · contact PI
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$569,928
R01 · FY2020 · CA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$551,141
R01 · FY2019 · CA
Ceramide Nanoliposomes in Combination with Focused Ultrasound for Treating Breast Cancer$183,204
R21 · FY2019 · CA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$545,802
R01 · FY2018 · CA
Ceramide Nanoliposomes in Combination with Focused Ultrasound for Treating Breast Cancer$171,520
R21 · FY2018 · CA
2018 Glycolipid and Sphingolipid Biology Gordon Research Conference$10,000
R13 · FY2018 · AI · contact PI
Targeted Sphingolipid Metabolism for Treatment of AML$2,019,502
P01 · FY2017 · CA
Combination of ceramide and immunotherapy in treatment of hepatocellular cancer$531,242
R01 · FY2017 · CA
Targeting Ceramide Glycosylation in AML$387,720
P01 · FY2017 · CA
Animal Modeling and Clinical Resources Core$340,284
P01 · FY2017 · CA
Targeting Acid Ceramidase in AML$319,896
P01 · FY2017 · CA
Novel Nanoparticle Therapy for Pancreatic Cancer$313,134
R01 · FY2017 · CA
Targeting Ceramide Metabolism in AML$300,315
P01 · FY2017 · CA · contact PI
Targeting Sphingosine Kinase in AML$224,096
P01 · FY2017 · CA
Synthesis and Nanoformulation Core$161,256
P01 · FY2017 · CA
Targeted Sphing''omics'' Core$136,170
P01 · FY2017 · CA
Administrative Core$102,933
P01 · FY2017 · CA
Biostatistics Core$46,832
P01 · FY2017 · CA
Targeted Sphingolipid Metabolism for Treatment of AML$2,019,502
P01 · FY2016 · CA
Targeting Ceramide Glycosylation in AML$387,720
P01 · FY2016 · CA
Animal Modeling and Clinical Resources Core$340,284
P01 · FY2016 · CA
Targeting Acid Ceramidase in AML$319,896
P01 · FY2016 · CA
Novel Nanoparticle Therapy for Pancreatic Cancer$313,189
R01 · FY2016 · CA
Targeting Ceramide Metabolism in AML$300,315
P01 · FY2016 · CA · contact PI
Targeting Sphingosine Kinase in AML$224,096
P01 · FY2016 · CA
Synthesis and Nanoformulation Core$161,256
P01 · FY2016 · CA
Targeted Sphing''omics'' Core$136,170
P01 · FY2016 · CA
Administrative Core$102,933
P01 · FY2016 · CA
Biostatistics Core$46,832
P01 · FY2016 · CA
Targeted Sphingolipid Metabolism for Treatment of AML$2,077,502
P01 · FY2015 · CA
Targeting Ceramide Glycosylation in AML$394,165
P01 · FY2015 · CA
Animal Modeling and Clinical Resources Core$346,728
P01 · FY2015 · CA
Targeting Acid Ceramidase in AML$326,341
P01 · FY2015 · CA
Novel Nanoparticle Therapy for Pancreatic Cancer$313,204
R01 · FY2015 · CA
Targeting Ceramide Metabolism in AML$306,760
P01 · FY2015 · CA · contact PI
Targeting Sphingosine Kinase in AML$230,541
P01 · FY2015 · CA
Synthesis and Nanoformulation Core$167,700
P01 · FY2015 · CA
Targeted Sphing''omics'' Core$142,613
P01 · FY2015 · CA
Administrative Core$109,378
P01 · FY2015 · CA
Biostatistics Core$53,276
P01 · FY2015 · CA
Targeted Sphingolipid Metabolism for Treatment of AML$1,929,328
P01 · FY2014 · CA
Targeting Ceramide Glycosylation in AML$391,023
P01 · FY2014 · CA
Animal Modeling and Clinical Resources Core$339,719
P01 · FY2014 · CA
Targeting Acid Ceramidase in AML$317,668
P01 · FY2014 · CA
Novel Nanoparticle Therapy for Pancreatic Cancer$303,857
R01 · FY2014 · CA
Targeting Ceramide Metabolism in AML$296,490
P01 · FY2014 · CA · contact PI
Targeting Sphingosine Kinase in AML$214,053
P01 · FY2014 · CA
Synthesis and Nanoformulation Core$146,087
P01 · FY2014 · CA
Targeted Sphing''omics'' Core$118,955
P01 · FY2014 · CA
Administrative Core$83,005
P01 · FY2014 · CA
Biostatistics Core$22,328
P01 · FY2014 · CA
Targeted Sphingolipid Metabolism for Treatment of AML$1,988,999
P01 · FY2013 · CA
Targeting Ceramide Glycosylation in AML$403,116
P01 · FY2013 · CA
Animal Modeling and Clinical Resources Core$350,227
P01 · FY2013 · CA
Targeting Acid Ceramidase in AML$327,492
P01 · FY2013 · CA
Novel Nanoparticle Therapy for Pancreatic Cancer$313,269
R01 · FY2013 · CA · contact PI
Targeting Ceramide Metabolism in AML$305,658
P01 · FY2013 · CA · contact PI
Targeting Sphingosine Kinase in AML$220,672
P01 · FY2013 · CA
Synthesis and Nanoformulation Core$150,605
P01 · FY2013 · CA
Targeted Sphing''omics'' Core$122,635
P01 · FY2013 · CA
Administrative Core$85,574
P01 · FY2013 · CA
Biostatistics Core$23,020
P01 · FY2013 · CA
The Role of Glycosphingolipids in Diabetic Retinopathy$366,843
R01 · FY2011 · EY · contact PI
The Role of Glycosphingolipids in Diabetic Retinopathy$382,178
R01 · FY2010 · EY · contact PI
PKC zeta as a Target for Ceramide$354,341
R01 · FY2010 · HL · contact PI
The Role of Glycosphingolipids in Diabetic Retinopathy$386,088
R01 · FY2009 · EY · contact PI
PKC zeta as a Target for Ceramide$354,378
R01 · FY2009 · HL · contact PI
PKC zeta as a Target for Ceramide$354,415
R01 · FY2008 · HL · contact PI
PKC zeta as a Target for Ceramide$354,450
R01 · FY2007 · HL · contact PI
PKC zeta as a Target for Ceramide$365,072
R01 · FY2006 · HL · contact PI
The Role of Ceramide in Diabetic Retinopathy$145,015
R03 · FY2006 · EY · contact PI
The Role of Ceramide in Diabetic Retinopathy$148,539
R03 · FY2005 · EY
ETHER-LINKED DIGLYCERIDES AND PROTEIN KINASE C ISOTYPES$269,325
R01 · FY2004 · HL
Role of Ceramide in Diabetic Retinopathy$148,573
R03 · FY2004 · EY
ETHER-LINKED DIGLYCERIDES AND PROTEIN KINASE C ISOTYPES$269,325
R01 · FY2003 · HL
ETHER-LINKED DIGLYCERIDES AND PROTEIN KINASE C ISOTYPES$269,325
R01 · FY2002 · HL
ETHER-LINKED DIGLYCERIDES AND PROTEIN KINASE C ISOTYPES$269,325
R01 · FY2001 · HL
SPHINGOLIPIDS AND MAP KINASES$197,629
R01 · FY2000 · DK